Frank Bennett

Major co-inventor of 3 approved drugs that led to 5 marketed products.

1. 2006: Noxafil (Posaconazole) oral suspension. approved by the FDA for serious fungal infections.

2. 2011: Victrelis (Boceprevir) first-in-class direct acting antiviral approved by the FDA for chronic hepatitis C.

3. 2012: Arlansa (Narlaprevir) licensed to R-Pharm and subsequently manufactured in Yaroslavl (Russia) for hepatitis C.

4. 2013: Posaconazole extended release formulation.

5. 2014: Posaconazole iv formulation.

Co-inventor of other clinical candidates and other potential drug entities for further development. Noteably.

1. Sch519884, a water soluble pro-drug of Posaconazole for iv administration.

2. Sch351754, a pro-drug of Ribavirin that improved the oral bioavailability of the anti-viral in rodents and higher species.

3. Co-inventor of clinical candidates HCV NS5B nucleoside monophophate prodrugs MK-2248 and MK-7680. Discovered L-005148988, a nucleoside triphosphate that exhibited an order of magnitude improvement in potency against wild-type NS5B polymerase over the triphosphate of the blockbuster, Sofosbuvir. This realization led to further work towards a low dose formulation.

4. Discovered a class of MBLIs that were not bacterial efflux substrates. Findings that were incorporated into the clinical candidate, MK-3402.

In addition to drug discovery, experience in several other field include.

1. Labeled compound synthesis. Both SIL and radioactive. Designed and executed the first synthesis of 14C-imipenem required for environment fate studies in Europe. Necessary for MK-7655a approval.

2. Brief (4 months) experience in Chemical Biology group.

3. Completed a one year experience in Merck DEL group.

Schering-Plough merged with Merck and Co. in November 2009. Please see Merck section for combined experience.